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AbstrACt
Objectives To evaluate the effectiveness of the 
Community-based Hypertension Improvement Project 
(ComHIP) in increasing hypertension control.
setting Lower Manya Krobo, Eastern Region, Ghana.
Participants All adult hypertensive community 
members, except pregnant women, were eligible for 
inclusion in the study. We enrolled 1339 participants, 
69% of whom were female. A total of 552 had a 
6-month visit, and 338 had a 12-month visit.
Interventions We report on a package of interventions 
where community-based cardiovascular disease (CVD) 
nurses were trained by FHI 360. CVD nurses confirmed 
diagnoses of known hypertensives and newly screened 
individuals. Participants were treated according to the 
clinical guidelines established through the project’s 
Technical Steering Committee. Patients received 
three types of reminder and adherence messages. We 
used CommCare, a cloud-based system, as a case 
management and referral tool.
Primary outcome Hypertension control defined as 
blood pressure (BP) under 140/90 mm Hg. Secondary 
outcomes: changes in BP and knowledge of risk factors for 
hypertension.
results After 1 year of intervention, 72% (95% CI: 
67% to 77%) of participants had their hypertension 
under control. Systolic BP was reduced by 12.2 mm 
Hg (95% CI: 14.4 to 10.1) and diastolic BP by 7.5 mm 
Hg (95% CI: 9.9 to 6.1). Due to low retention, we were 
unable to look at knowledge of risk factors. Factors 
associated with remaining in the programme for 
12 months included education, older age, hypertension 
under control at enrolment and enrolment date. The 
majority of patients who remained in the programme 
were on treatment, with two-thirds taking at least two 
medications.
Conclusions Patients retained in ComHIP had 
increased BP control. However, high loss to follow-up 
limits potential public health impact of these types of 
programmes. To minimise the impact of externalities, 
programmes should include standard procedures 
and backup systems to maximise the possibility that 
patients stay in the programme.
IntrOduCtIOn   
Globally, raised systolic blood pressure (SBP) 
is one of the greatest risk factors for disability.1 
Hypertension is generally considered to be 
the level of raised BP where medications show 
a reduction in clinical events in randomised 
trials. This is generally accepted as ≥140 SBP 
mm Hg or ≥90 diastolic mm Hg (DBP).2 
Evidence shows that lowering hyperten-
sive individual’s BP with antihypertensive 
drugs reduces the risk of further cardio-
vascular events; with a reduction in stroke 
by an estimated 35%–40% and a 20-25% 
reduction in myocardial infarction and heart 
failure.3–5 While average age-standardised 
BP is decreasing in most high-income coun-
tries, it is increasing in most low-income and 
middle-income countries6 with 32%–50% of 
adults estimated to be hypertensive in sub-Sa-
haran Africa.7
The Prospective Urban Rural Epidemi-
ology study showed that despite high levels 
of hypertension worldwide, only 34% of 
strengths and limitations of this study
 ► The community-based Hypertension Improvement 
Project is a large cohort study testing a communi-
ty-based model of hypertension care.
 ► Trained community-based cardiovascular nurses 
conducted screening, diagnosis and management of 
hypertension patients.
 ► Patients were sent three types of short message 
service (SMS), daily reminders to take their medi-
cations, appointment reminders and weekly health 
education messages.
 ► Protocol stated that blood pressure would be 
checked with a minimum of three serial readings 
at regular intervals, but at a minimum of 6-monthly 
intervals.
 ► A limitation of the study was that it did not include 
a control group.
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Africans are aware of their hypertension status, only 
31.3% receive any treatment and only 6.5% have their BP 
under control.8 Our recent study of hypertension prev-
alence in the Lower Manya Krobo, Ghana, showed that 
only 2.1% of hypertensives had their BP under control.9
Because of the great burden of hypertension in sub-Sa-
haran Africa and the poor rate of hypertension control, 
innovative methods for hypertension management are 
needed. Launched in 2015, the Community-based Hyper-
tension Improvement Project (ComHIP) introduced 
as an innovative model for hypertension control at the 
community level. ComHIP is a public–private partnership 
between the Ghana Health Service (GHS), FHI 360 and 
the Novartis Foundation.
The aim of ComHIP is to improve hypertension 
management and control in the Lower Manya Krobo 
District in the Eastern Region of Ghana. The programme 
includes a package of interventions composed of six 
components (online supplementary figure 1), aimed at 
increasing access to hypertension services at the commu-
nity level. Screening in the community is provided by 
cardiovascular disease (CVD) nurses and community 
health officers (CHOs), as well as through local private 
sector drug shops called licensed chemical sellers (LCS). 
Ongoing hypertension management is provided by CVD 
nurses or, for those with comorbidities or severe condi-
tions, at district hospitals. Patients are encouraged to 
routinely monitor their BP by having their BP measured 
at an LCS. The various service providers are linked 
through a cloud-based system, which revolves around 
bringing hypertension care into the community. Physi-
cians, community-based CVD nurses, CHOs and LCS staff 
were trained by FHI 360 to provide specific services.
For instance, CVD nurses conduct hypertension 
screening, and confirmation of hypertension diagnosis, 
staging of the degree of hypertension, assessment of other 
CVD risk factors, counselling, monitoring and follow-up, 
and trained LCS conduct community BP screening and 
awareness raising. Further information can be found in 
the online supplementary material.
The ComHIP programme is being independently eval-
uated by the University of Ghana School of Public Health 
and the London School of Hygiene & Tropical Medi-
cine with a mixed-methods approach through a series of 
quantitative and qualitative studies. These studies include 
repeat cross-sectional surveys within the intervention and 
comparison districts to track overall awareness and prev-
alence of hypertension; a cohort of hypertensive persons 
included in ComHIP to assess hypertension control; a 
cost-effectiveness evaluation; a study to assess the level of 
patient-centeredness within the programme and a quali-
tative assessment of ComHIP stakeholders. In this paper, 
we report the results of the cohort study.
Objectives
The objective of this study was to evaluate the effective-
ness of ComHIP for controlling hypertension in patients 
with hypertension enrolled in the ComHIP programme.
MethOds
study design
The study was a prospective cohort study, which included 
all patients recruited into the ComHIP programme.
setting
The study was conducted in Lower Manya Krobo, a munic-
ipality in the Eastern Region of Ghana. This is a peri-
urban setting approximately 2 hours from the national 
capital, Accra, with a population of approximately 89 246, 
of whom 84% live in urban areas.10 Recruitment began 
in October 2015 and ended in December 2016.
Training
FHI 360 and the Ministry of health (MoH) conducted 
training. Training duration ranged from 3 days for LCS 
and physicians, to 6 days for CVD nurses. Aside from 
the general training package (BP screening including 
the recommended standard operating procedures for 
BP checking, lifestyle modification counselling, inter-
viewing/counselling techniques and treatment adher-
ence counselling) offered to all personnel, CVD nurses 
and physicians received additional training on hyperten-
sion diagnosis, assessing the risk of patients,  assessing for 
target organ damages (TODs), and training on drugs for 
the management of hypertension and their side effects 
and contraindications.
Participants were issued a certificate of participation 
signed by the cardiologist specialist who conducted the 
training and the director general of the GHS. Also, as is 
done by the GHS, the continuous learning logbooks of 
the GHS personnel were endorsed by the project to docu-
ment the training received.
Participants
Patients were enrolled in the programme if (1) they were 
known hypertensives or (2) had an elevated BP reading 
at any ComHIP screening. Any individual living in Lower 
Manya Krobo, 18 years or older, was eligible, except preg-
nant women. Patients had to have access to a mobile phone 
to be enrolled in the programme. However, in order to 
negate the loss of patients, patients without phones were 
not necessarily excluded based on this; rather, they were 
encouraged to provide phone numbers of a willing third 
party who lived nearby.
Intervention
Community members were screened by CHOs, LCS or 
CVD nurses, using Omron M6 BP monitors that came 
with a cuff size of 42 cm,  the second largest cuff size 
in the market for those machines. Though the project 
requested for nurses to report cases of patient with bigger 
upper arms that required bigger cuff sizes, throughout 
the implementation, no such reports were received. The 
average of three serial readings was used to confirm hyper-
tension diagnosis. Patients who were at risk of hyperten-
sion (SBP≥120, but <140) were given health education. 
All patients with SBP≥140 or DBP≥90 were referred to 
a CVD nurse for diagnosis. Patients with SBP≥180 or 
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DBP≥110 were enrolled and referred to the physician for 
urgent care. Patients that were considered to have severe 
hypertension (SBP≥180 or DBP≥110 or SBP between 
160 and 179 or DBP 100 and 109 with one or more risk 
factors, or any evidence of organ damage see online 
supplementary appendix A) were referred for manage-
ment by a physician at one of the district hospitals, until 
their BP was stable, and then they were returned to CVD 
nurses for care. All other patients were managed by CVD 
nurses.
Patients with hypertension were enrolled and followed 
for at least 1 year. All patients’ interactions (with LCS, 
CHOs, CVD nurses, and community and hospital pharma-
cist and doctors) were recorded and uploaded through the 
CommCare platform. Patients were requested to present 
for appointments at the following intervals: monthly BP 
monitoring appointments; monthly, bi-monthly or quar-
terly review visits (depending on risk factors and personal 
factors) and 6-monthly follow-up assessments. Partici-
pants were recruited from October 2015 until December 
2016, and followed through December 2017. Guidelines 
for patient visits can be found in the supplementary mate-
rials (online supplementary table 1, online supplemen-
tary figure 2, online supplementary appendix A).
All enrolled participants were treated based on the 
same clinical guidelines established through the project’s 
Technical Steering Committee, which included senior 
members of the GHS. The treatment goal was to improve 
BP of all patients to below 140/90 mm Hg. Participants 
were initiated onto drug therapy and supplemented 
with non-drug therapy (lifestyle modification including 
low-salt diets, increased fruit and vegetable diet, reduc-
tion in alcohol consumption, smoking cessation and 
regular aerobic exercise) irrespective of their risk level. 
The decision to initiate monotherapy or multiple drug 
therapy depended largely on the level at which the partic-
ipant's BP was above goal and the overall risk level of 
patients. Recommended drugs and dosages are found 
in online supplementary table 2. Patient’s response to 
antihypertensives was reviewed every 3 months if possible 
and modified based on recommended guidelines if 
required. In Ghana, there is a system of National Health 
Insurance (NHI) in which every Ghanaian is required 
to enrol. The scheme provides select medications at no 
cost for anyone who has a valid NHI card. Although the 
NHI scheme (NHIS) does not attempt to treat all diseases 
suffered by insured members, over 95% of disease condi-
tions that afflict us are covered by the NHIS. Services can 
be accessed at accredited health facilities.
CommCare is a vital component of ComHIP. It serves 
as a case management system, referral tool and job aid 
for providers. The CommCare database is linked with 
an SMS platform to automatically send daily adherence 
reminders, weekly healthy living tips, and consultation 
and prescription refill reminders to enrolled patients. 
These messages are sent via text or voice SMS with four 
language choices. The programme is described in more 
detail elsewhere.9 Briefly, through CommCare, patients 
diagnosed with severe hypertension or coexisting condi-
tions are automatically referred to a physician. All patients 
enrolled in ComHIP receive SMS daily for medication 
reminders, weekly for health education and appoint-
ment and screening reminders. CommCare also provides 
a cloud-based health records system that links patients’ 
records with the SMS system. The SMS component of 
the project was implemented by a third party Viamo; to 
facilitate the link between the two systems, a bridge was 
built to automatically relay relevant information from 
the projects cloud-based health records to the Viamo 
messaging platform. To ensure confidentiality, only infor-
mation relevant to schedule appointments is relayed to 
the Viamo platform (ie, patient code, date of visit, type of 
visit, next review or refill appointment, patient’s phone 
number, preferred language, time of receipt of message 
and format of the message, referral details and BP). When 
a visit is missed, the system automatically relays back to the 
CVD nurse who enrolled the patient or is managing the 
patient via text message for the nurse to trace the patient. 
Due to operational problems, there was a break in service 
in CommCare that began on 12 May 2016 for a period of 
at least 3 months.
Variables
Main outcomes
The main outcomes of interest were hypertension control 
(<140/90 mm Hg) and changes in SBP and DBP. Because 
of the low follow-up rate, we also used appointment 
around 6 months, and appointment around 12 months as 
outcomes of interest.
Other variables
Other variables included knowledge of risk factors for 
hypertension, demographic factors including age, gender 
and marital status, risk factors, such as body mass index 
(BMI), awareness of hypertension (defined as having 
knowledge of a previous diagnosis of hypertension), 
having hypertension under control prior to enrolment 
and having previous diagnoses of other heart diseases, 
and socioeconomic factors. A full list of variables is found 
in table 1.
data collection
Data were collected on BP using standardised proto-
cols. At 6 and 12 months, forms were administered by 
healthcare providers to collect information on patient 
knowledge of risk factors for hypertension and health 
behaviours.
All data were collected and downloaded from the 
CommCare platform. Initially, data were intended to be 
analysed from the patient knowledge/behaviour forms 
used at 6-month and 12-month follow-up appointments. 
Due to poor levels of follow-up, any appointment between 
5 and 7 months after enrolment was used for the 6-month 
appointment analysis, and any appointment between 11 
and 13 months after enrolment was used for the 12-month 
appointment analysis.
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sample size
This cohort study included all the patients recruited in 
the ComHIP programme and a specific sample size was 
not calculated. However, in the protocol, we assumed 
that the total district population is about 90 000; about 
30 000 of whom are adults, and about 36% (12 000) are 
estimated to be hypertensive. Assuming that about 10% 
of the adults with hypertension in the district will be 
included in the ComHIP programme, we would have a 
cohort of 1200 patients with hypertension.
We estimated that a cohort study of 1200 patients with 
hypertension would provide a power greater than 90% 
(with an alpha error of 0.05) to detect a twofold increase 
of control of hypertension (from 4% to 8%).
Patient and public involvement
Community members, including community leaders, 
were first involved through a stakeholder workshop. 
In this workshop, community members shared their 
thoughts, knowledge and concerns about health in 
Table 1 Characteristics of participants in the study at 
baseline
Characteristic
% all 
patients*
% 6 month 
appointment†
% 12 month 
appointment‡
Number 1339 552 338
Referred by
  LCS 23.9 23.4 24.3
  CHO 45.0 40.8 38.5
  CVD nurse 23.3 25.4 26.9
  Other 7.8 10.5 10.4
Sex
  Male 30.8 32.3 30.7
  Female 69.2 67.8 69.3
Age class
  30–44 17.9 14.7 13.6
  45–54 23.5 21.7 24.3
  55–64 27.3 31.9 32.0
  65+ 31.4 31.7 30.2
Hypertension stage
  Normal 26.4 38.6 41.7
  Stage I 39 39.9 39.4
  Stage II 19.6 14.5 13.0
  Stage III 14.9 7.1 5.9
Mean BP
  DBP 90.8 87.6 86.9
  SBP 149.0 143.3 141.2
Education
  No formal education 37.0 32.3 31.4
  Primary 41.7 431 45.6
  Secondary 16.1 18.5 14.8
  Higher 5.2 6.2 8.3
Ethnicity
  Akan 4.2 28.6 21.4
  Dangme 69.5 42.2 26
  Ewe 22 39.3 22.4
  Other or do not know 4.3
Religion
  Christian 96 97.6 97.9
  Muslim 3.2 1.5 1.2
  Traditional 0.5 0.4 0.3
  None 0.3 0.5 0.6
Marital status
  Never married 5.7 5.1 3.6
  Married/cohabiting 54.4 54.7 57.7
  Separated/divorced 5.5 14.1 15.4
  Widowed 26.1 25.9 23.1
  No response 0.2 0.2 0.3
Household income
  Less than 728 GHC 18.7 17.0 17.2
  728–1020 GHC 17.4 20.8 19.8
Continued
Characteristic
% all 
patients*
% 6 month 
appointment†
% 12 month 
appointment‡
  1021–1098 GHC 6.4 5.3 6.5
  1099–1263 GHC 5.0 4.9 4.7
  More than 1263 GHC 12.3 11.1 11.8
  Do not know/no 
response
40.2 40.9 39.9
Aware of hypertension status
  Never had BP 
measured
18.7 17.6 16.3
  Was not aware 12.9 11.4 10.7
  Aware 68.5 70.8 73.1
Taking treatment
  Never diagnosed 31.5 29.2 26.9
  Diagnosed and no 
treatment
18 15.0 16.0
  Treatment 50.3 55.6 56.8
  Do not know 0.2 0.2 0.3
BMI
  Underweight 
(BMI<18.5)
5.4 4.9 5.0
  Normal weight (BMI 
18.5–24.9)
43.7 44.8 43.2
  Overweight (BMI 
25–29.9)
29.2 30.1 32.5
  Obese (BMI 30+) 21.7 20.3 19.2
*All patients with hypertension enrolled in the cohort.
†Patients with hypertension with 6-month appointment/follow-up.
‡Patients with hypertension with a 12-month appointment/follow-
up.
BMI, body mass index; BP, blood pressure; CHO, community 
health officers; CVD, cardiovascular disease; DBP, diastolic blood 
pressure; LCS, licensed chemical sellers; SBP, systolic blood 
pressure. 
Table 1 Continued 
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general, Non-communicable disease-related conditions 
and access to healthcare. Furthermore, community 
members were made aware of the hypertension project 
planned to be initiated in their community. This informa-
tion was considered in finalising the design of the service 
delivery model and the development of prevention, 
education and behaviour change messages.
Patients were recruited into the project through free 
screening offered at (1) local drug shops, names LCS; 
(2) Community Health Planning Service (CHPS) sites 
or (3) community pharmacies. There were commu-
nity screening activities and radio programmes through 
which community members were educated on the project 
and hypertension in general. In addition, ComHIP staff 
conducted annual stakeholder meetings to provide 
updates to community members on the project progress.
statistical methods
We recoded exposures to reduce the number of levels 
and for missing values, for all the previous diagnosis/
awareness, we have coded ‘missing’ or ‘not known’ or ‘no 
answer’ as 0, so that value 1 always means ‘patient knows 
of a previous diagnosis’ while value 0 means anything else 
(patient does not know or answer is missing). Because 
there were few previous diagnoses of each specific event 
(MI, stroke, diabetes etc), we created a variable with value 
1 if any diagnosis was present and 0 if none was present.
For education, we assumed that those that did not 
know (48) or did not respond (26) did not have previous 
formal education (the largest group). We then grouped 
education in four levels: (1) no formal education, (2) 
primary (completed or not), (3) secondary (completed 
or not) and (4) higher (university).
For marital status, we made four categories: (1) never 
married, (2) married or cohabiting, (3) separated or 
divorced and (4) widowed.
We described the distribution of each variable at 
baseline, 6 months and 12 months follow-up, although 
comparisons cannot be done directly due to the large 
number of individuals that did not have a follow-up. To 
study what variables might affect the patient staying for 
12 months in the programme, we ran a logistic regression 
for the binary outcome variable: ‘patient had 12-month 
visit (Y/N)’. To consider the loss to follow-up (patterns 
of visits), we separated the individuals into four different 
groups: (A) those individuals that did not come to any 
follow-up visit, (B) those that came only to the 6-month 
visit, (C) those that came only to the 12-month visit and 
(D) those that came to both follow-up visits.
We described the absolute values of BP (SBP and DBP), 
the proportion of patients with BP under control and the 
distribution of hypertension stages for each of these groups 
in each of the visits. We estimated the average changes of 
BP for each group at each follow-up visit and we compared 
the changes between groups with Student’s t-tests. We 
compared the mean of SBP and DBP between the groups 
with analysis of variance  (ANOVA) models. To compare 
the proportion of patients with hypertension control or 
the distribution of hypertension stages between groups, 
we used χ2 tests. To test the changes of variables within 
groups, we used paired t-tests for continuous variables and 
marginal homogeneity tests for categorical variables.
results
Participants
A total of 18 339 individuals, 18 years and older, were 
screened, 4118 were referred to CVD nurses to confirm 
diagnosis, and of those 1339 were enrolled, 76 (5.7%) 
were considered low-risk (stage 1 BP, which is SBP 140–159 
or DBP 90–99 without any TODs, comorbidities or ≥2 risk 
factors), 559 (41.7%) were moderate risk (stage 2, which is 
SBP 160–179 or DBP 100–109 without any TODs, comorbid-
ities or ≥2 risk factors or stage 1 BP with TODs, comorbidities 
or ≥2 risk factors) and 704 (52.6%) were considered high-
risk (stage 3, which is SBP≥180 or DBP≥101 without any 
TODs, comorbidities or ≥2 risk factors or stage 2 BP with 
TODs, comorbidities or ≥2 risk factors).
General characteristics of the cohort
The average age of the cohort was 58 years. Everyone was 
enrolled into the cohort by CVD nurses. Of the 1339 people 
enrolled in the cohort, 24% were referred to ComHIP by 
LCS, 45% were referred by CHO, 23% were referred by 
CVD nurses, 3% were through physicians and 5% were 
referred through other channels. About 69% of the cohort 
was female and 31% male. Other characteristics of people 
enrolled in the cohort are found in table 1.
Other risk factors
About 5.4% of the sample was underweight, 43.7% was 
normal, 29.2% was overweight and 21.7% was obese. The 
mean BMI at enrolment in the cohort was 26.1 (95% CI: 
25.82 to 26.4). 
We did not analyse smoking, cholesterol or diabetes as 
only 1% of the sample were smokers, 3.5% reported having 
had a previous cholesterol test and only 28% had a previous 
diabetes test.
BP at enrolment
The average SBP was 147.2 (SD 22.1) mm Hg, and average 
DBP was 89.9 (SD 13.3) mm Hg. At enrolment, 917 (68.5%) 
had a previous diagnosis of hypertension, of which 654 
(71.3%) were already taking some antihypertensives, and 
297 (32.4%) had their BP under control.
BP management
Of 1339 enrolled in the study, 712 (53.2%) did not come for 
a follow-up (group A), 289 (21.6%) had only a 6-month visit 
(group B), 75 (5.6%) had only the 12-month visit (group C) 
and 263 (19.6%) had both visits (group D). In total, only 552 
(41%) had a 6-month follow-up appointment, and only 338 
(25%) had a 12-month follow-up appointment.
Loss to follow-up and characteristics of those who stayed in the 
study
Patients with their hypertension already under control were 
more likely to present for care. The variable that showed the 
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greatest association with likelihood of having a 6-month or 
12-month appointment was enrolment month. Participants 
who enrolled earlier were much more likely to stay in the 
programme than those who enrolled later (table 1).
Multivariate analysis suggested that recruitment before 
12 May 2016 (1 year before the break in service), age, 
education and hypertension under control in the first visit 
showed significant associations with having a 12-month 
appointment. Recruitment after 12 May 2016 reduced the 
chances of coming to further visits, the older the patient and 
the higher the education level, the higher the chances that 
the patient would come to the follow-up visits. Patients with 
controlled hypertension at enrolment were nearly twice as 
likely to come to follow-up visits. None of the other variables 
showed significant associations (table 2).
Changes in BP
Because 12-month follow-up was below 30%, we did not look 
at overall changes in BP, but we did look at overall changes in 
BP in those that remained in the study at 6 and 12 months.
On average, patients who enrolled and presented 
for a follow-up appointment at around 6 months had 
a 10.3 mm Hg reduction in SBP (95% CI: 12.0 to 8.6) 
and a 6.3 mm Hg reduction in DBP (95% CI: 7.2 to 5.2) 
(table 3). There was a greater reduction in those patients 
who had a follow-up appointment at 1 year, when there 
was a 12.2 mm Hg reduction (95% CI: 14.4 to 10.1) in SBP 
and a 7.5 mm Hg (95% CI: 9.9 to 6.1) reduction in DBP 
after 1 year in the programme. Not all patients who had a 
12-month appointment also had a 6-month appointment, 
263 had both, and they had an 11.9 mm Hg reduction 
(95% CI: −14.3 to –9.5) in SBP and 7.1 mm Hg reduction 
(95% CI: −8.6 to –5.5) in DBP (table 3).
Knowledge of risk factors
Because of the poor retention, we were unable to comment 
on knowledge or risk factors.
There was also a significant reduction in hypertension 
stage, with a lower percentage of patients with hypertension 
having stage III hypertension over time (table 4).
Table 2 Multivariate analysis of baseline characteristics 
associated with staying in the programme for 12 months
OR (95% CI) P value
Enrolled year prior to the break 0.46 (0.35 to 0.60) 0.00
Sex 0.88 (0.63 to 1.24) 0.48
Age (1-year increments) 1.01 (1.00 to 1.02) 0.03
BMI 1.00 (0.97 to 1.02) 0.90
Education reference category: no formal education
  Primary education 1.41 (1.03 to 1.93) 0.03
  Secondary education 1.13 (0.73 to 1.73) 0.59
  Higher education 2.42 (1.33 to 4.43) 0.004
Reference category: never 
married
  Married/cohabitating 1.77 (0.90 to 3.48) 0.10
  Separated/divorced 1.86 (0.90 to 3.87) 0.10
  Widowed 1.27 (0.61 to 2.64) 0.52
  Household size 1.01 (0.95 to 1.07) 0.69
  Hypertension control 1.93 (1.47 to 2.54) <0.001
  Awareness of hypertension 1.00 (1.00 to 1.00) 0.97
  Hypertension treatment 1.00 (0.99 to 1.00) 0.33
  Any other previous diagnosis 0.86 (0.69 to 1.07) 0.18
  Confidence in management 
of hypertension
1.00 (1.00 to 1.01) 0.63
BMI, body mass index.
Table 3 Changes in BP means and hypertension control by patterns of visits
Groups N Visit
SBP DBP HT control
Mean (SE)
Mean difference 
(95% CI) Mean (SE)
Mean difference 
(95% CI) % (95% CI)
All patients 1339 E 147.2 (0.60) 89.9 (0.36) 31% (29% to 34%)
552 6 m 132.9 (0.80) −10.3 (−12.0 to −8.6) 81.3 (0.47) −6.3 (−7.3 to −5.2) 69% (65% to 73%)
338 12 m 128.9 (1.05) −12.2 (−14.4 to −10.1) 79.4 (0.61) −7.5 (−8.9 to −6.1) 72% (67% to 77%)
(A) No visits 712 E 150.4 (0.85) 91.7 (0.49) 25% (21% to 28%)
(B) Only 6 m 289 E 146.4 (1.28) 89.0 (0.77) 34% (29% to 40%)
6 m 135.7 (1.15) −10.1 (−13.2 to −8.1) 82.7 (0.68) −6.3 (−7.8 to −4.8) 61% (55% to 67%)*
(C) Only 12 m 75 E 145.9 (2.62) 90.2 (1.63) 36% (25% to 48%)
12 m 132.5 (2.56) −13.5 (−18.5 to −8.6) 81.0 (1.38) −9.2 (−12.4 to −6.0) 71% (59% to 81%)*
(D) 6 and 12 m 263 E 139.8 (1.18) 86.1 (0.80) 43% (37% to 50%)
6 m 129.8 (1.08) −10.0 (−12.2 to −7.7) 79.8 (0.63) −6.3 (−7.8 to −4.8) 77% (72% to 82%)*
12 m 127.9 (1.13) −11.9 (−14.3 to −9.5) 79.0 (0.67) −7.1 (−8.6 to −5.5) 72% (66% to 78%)*
*The comparison of these intervals with enrolment visit of the same group produces all p values <0.0001.
BP, blood pressure; DBP, diastolic blood pressure; E, enrolment; HT, hypertension, m, month; SBP, systolic blood pressure; SE, 
standard error 
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Awareness
Overall awareness of hypertension status in the overall 
cohort was 68.5% at enrolment. Individuals who stayed 
in the programme longer were more likely to be aware of 
their hypertension status. About 70.8% of individuals who 
stayed in the programme for 6 months were aware of their 
hypertension status, and 73.1% of those who stayed in the 
programme for 12 months were aware of their hypertension 
status (table 1).
Treatment
Treatment increased between enrolment and 6-month and 
12-month appointments. Although only 44.2% of patients 
were receiving any medication at enrolment, the majority 
were being treated at 6 months (90.4%) and at 12 months 
(92.2%). At enrolment, the majority of patients who were 
on treatment were taking a calcium channel blocker (CCB) 
(36% of all patients), but at 6 months, the majority were on 
diuretics (75.9%) followed by a CCB (69.5%). The same 
pattern was found at 12 months with 79.8% taking diuretics, 
and 71.5% taking a CCB (table 5).
In patients who had a 6-month appointment, 24.1% were 
taking only one medication, 32% were taking two medica-
tions and over 30% were taking more than two medications. 
In patients who had a 12-month appointment, 23% were 
taking one medication, 32.6% were taking two medications 
and over 32% were taking more than two medications.
Control
There was an increase in BP control in patients who 
remained in the programme (table 3); however, patients 
who stayed in the programme were more likely to have 
Table 4 Distribution of hypertension stage in each group in each visit. The p values are extracted from: (1) Χ2 tests to 
compare that row with group A of no follow-up and (2) from marginal homogeneity tests comparing the distribution of the same 
group in enrolment visit
Groups by patterns of visits N Visit No HT Stage I Stage II Stage III P value
All patients 1339 1 m 31.0% 39.0% 18.4% 11.6%
552 6 m 68.7% 19.7% 9.4% 2.2% <0.001 (2)
338 12 m 71.9% 19.5% 6.5% 2.1% <0.001 (2)
(A) No follow-up 712 1 m 24.6% 38.7% 21.5% 15.2%
(B) Only 6-m visit 289 1 m 34.3% 39.4% 17.0% 9.3% 0.002 (1)
289 6 m 60.9% 24.2% 12.1% 2.8% <0.001 (2)
(C) Only 12-m visit 75 1 m 36.0% 36.0% 17.3% 10.7% 0.167 (1)
75 12 m 70.7% 14.7% 10.7% 4.0% <0.001 (2)
(D) 6-m and 12-m visit 263 1 m 43.4% 40.3% 11.8% 4.5% <0.001 (1)
263 6 m 77.2% 14.8% 6.5% 2.2% <0.001 (2)
263 12 m 72.3% 20.9% 5.3% 1.5% <0.001 (2)
m, month.
Table 5 Treatment pattern in the cohort at enrolment, 6 months and 12 months with p values for differences
Treatment Enrolment 6 months P change 12 months P change
Diuretic 21.66% 75.89% 0.00000 79.83% <0.00001
Calcium CB 36.07% 69.46% 0.00000 71.47% <0.00001
Beta-blocker 3.14% 8.93% 0.00000 9.51% 0.00001
ACE inhibitor 6.72% 22.5% 0.00000 21.61% <0.00001
ARB 2.54% 12.5% 0.00000 13.54% <0.00001
Other 3.66% 15.89% 0.00000 17.87% <0.00001
Any 44.29% 90.36% 0.00000 92.22% <0.00001
0 medications 55.71% 9.64% 0.00000 7.78% <0.00001
One medication 19.42% 24.11% 0.21013 23.05% 0.62722
Two medications 20.46% 31.96% 0.00040 32.56% 0.00811
Three medications 4.18% 23.93% 0.00000 24.78% <0.00001
Four medications 0.22% 6.96% 0.00000 8.07% <0.00001
Mean 0.74 2.05 0.00000 2.14 <0.00001
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blockers; CB, channel blocker. 
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their BP under control on enrolment. In the group of 
patients that did not have a second appointment (group 
A), the baseline BP control was 25% while in the other 
groups (B, C and D) was 34%, 36% and 43%, respectively. 
These differences were statistically significant (table 4). 
The BP control increased to 69% (95% CI: 65% to 73%) 
in the individuals that visited at 6 months. In the patients 
that had the 12-month visit, the control increased to 
72% (95% CI: 67% to 77%). Of patients who had both 
a 6-month and 12-month follow-up appointment, the 
control increased to 77% (95% CI: 72% to 82%) at 
6 months, but slightly decreased to 72% at 12 months 
(95% CI: 66% to 78%) (table 3, table 4).
dIsCussIOn
summary of results
Of 1339 patients enrolled in ComHIP, only 552 (41%) 
had a follow-up appointment at 6 months, 338 (25.2%) 
had a follow-up appointment at 12months and 263 (20%) 
had both 6-month and 12-month appointments. Partic-
ipants who had more education, were older, had their 
hypertension under control at enrolment, or who had the 
opportunity to spend at least a year in the programme 
before the break in service were more likely to attend 
appointments at 6 and/or 12 months.
Among the group of patients who continued in the 
programme for 6 or 12 months, we found strong evidence 
of a reduction in DBP and SBP, and an increase (from 
under half to more than two-thirds) of hypertension 
control. We also found strong evidence of an increase of 
the patients under treatment, of the number of medica-
tions received per patient and a decrease in the number 
of individuals with severe hypertension.
Comparison with other studies
Other studies evaluating task sharing for hypertension 
management have shown modest levels of success. For 
example, one randomised controlled study conducted 
in Ghana using task sharing (but supplying free medi-
cations) showed greater reductions in SBP in patients 
randomised to the arm that included trained nurses, as 
compared with the one that just provided free medica-
tions and health insurance.11
The poor follow-up reported in our study is not unex-
pected. Many studies have shown poor levels of follow-up 
or adherence to clinic appointments. In one study 
conducted in three primary care clinics in Kibera, Kenya, 
between 2010 and 2012, 1465 hypertensive or diabetic 
patients were identified. Of these, 31% of patients were 
lost to follow-up. Of these, 55% of non-diabetic patients 
had their BP under control by 24 months, but only 28% 
of diabetic patients.12
In another study conducted in Kibera, Kenya, between 
2015 and 2016, 3861 patients with hypertension were 
identified in health centres or clinics. Of those, 3069 
patients did not complete 6 months of follow-up (79%). 
Of those, patients who remained in the programme over 
6 months, they found 63% adherence to appointments.13
In a study conducted in the slums of Nairobi, only 3.4% 
of participants showed completed compliance with the 
programme. About 30% only showed up for one appoint-
ment, and 5% only had two visits. Similar to our study, 
they found that patients who remained in the programme 
showed significant reductions in SBP and DBP.14
In a study done in two sites (one rural and one urban) 
in Malawi, of 4075 patients referred for clinical care, only 
61% attended their referral appointments. Of those, 47% 
of patients with hypertension were still in contact after 
24 months. Similar to our findings, they found uptake in 
care to be higher in older patients, being on antihyper-
tensives prior to enrolment, and not being in employ-
ment. Unlike our study, they found that females were 
more likely to be retained in care.15
Similarly, a study of hypertensive and diabetic patients 
in rural Cameroon found that only 18.1% of participants 
were still in care after 1 year. However, similar to our 
study, they found significant decreases in SBP and DBP in 
patients with hypertension with at least two documented 
visits.
strengths and limitations
A major strength of this study is unlike most other hyper-
tension programmes, ComHIP uses existing GHS proto-
cols and medications and does not require outside funds 
or intervention for medications. This means that there 
is a much greater chance of long-term sustainability of 
the programme as it does not rely on outside sources for 
medications.
Limitations of the study include that data were only 
available for encounters with service providers within the 
ComHIP network. Any appointments with doctors and 
pharmacists (licensed or unlicensed) that were not part 
of ComHIP would not have been registered, so it is 
possible that patients were obtaining antihypertensives 
from non-licensed sellers, which would not be captured 
in the ComHIP database. Another limitation of ComHIP 
was that the cohort did not have a control.
Due to the extremely poor follow-up, it is not possible 
to generalise our findings regarding the impact on BP 
control to other studies, other than to emphasise the 
importance of effective strategies to promote follow-up. 
Finally, it is important to remember that nearly 70% of 
the initial cohort was aware of their hypertension status 
and about half were taking medications, which is a much 
higher proportion than in the general population. While 
this was done in ComHIP to ensure access to hyperten-
sion management to community members who other-
wise would not have been able to access services, it is an 
important consideration when considering generalis-
ability to the overall population.
Interpretation
In 25% of people who had a 12-month appointment, 
there was strong evidence of an increase of the patients 
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receiving medications, the average number of medi-
cations received per patient and the level of hyperten-
sion control; we also found a reduction in both BP and 
hypertension status. However, like most other studies 
in the region, the high loss to follow-up highlights that 
innovative hypertension programmes, such as ComHIP, 
need to develop better ways to retain patients within the 
programme.
Community-based hypertension programmes in 
resource-poor setting often are complex to carry out and 
are prone to poor follow-up. There are many possible 
reasons that follow-up in our study was low.
The factor most associated with retention in the 
programme was enrolment date. This is significant as due 
to operational issues, there was a gap of CommCare util-
isation for 3 months. Anecdotally, FHI 360 ComHIP staff 
learnt that this gap in CommCare service had caused both 
service providers and staff to believe that the interven-
tion had stopped, which may have resulted in a low rate 
of completion of follow-up appointments. Considering 
difficulties associated with community-based studies in 
low-resource settings, it is imperative to ensure continuity 
of service. Other factors that could cause this association 
may be healthcare professional fatigue; engaging patients 
to present for appointments may require considerable 
effort, such as multiple phone calls and personal interac-
tion, for which the CVD nurses did not receive additional 
monetary compensation. It is possible that over time, the 
enthusiasm of the CVD nurses for the intervention may 
have waned. Also, as in any low-resource settings, there is 
a great deal of workforce turnover; FHI 360 recognised 
this early in the implementation and trained extra staff to 
bridge the gaps; however, it is still possible that new health-
care providers who replaced them may not have had the 
same level of training. A complementary component of 
the evaluation that includes qualitative research with 
different ComHIP stakeholders is underway to analyse in 
depth the possible reasons that may have caused people 
to not adhere to the programme. (See Adler et al Barriers 
and facilitators to the implementation of a communi-
ty-based hypertension improvement project in Ghana: 
a qualitative study and Laar et al Health system challenges 
to hypertension and related non-communicable diseases 
prevention and treatment: perspectives from Ghanaian 
stakeholders.)
Lastly, our study found that older individuals were 
more likely to continue in care, this was found in at 
least one other study15 but was not reported on in most 
studies. This could be because older patients may have 
more time to attend clinics. Patients with their hyperten-
sion under control were about twice as likely to stay in 
the programme. This is not surprising as they had already 
exhibited better health-seeking behaviours.
recommendations
For patients enrolled and who continued in the 
programme, we found an important impact on the 
management of hypertension and in BP control. 
However, the high loss to follow-up of patients recruited 
limits the potential public health impact of these types of 
programmes. In order to minimise the impact of exter-
nalities (such as the CommCare service gap in ComHIP), 
programmes should have standard procedures and 
backup systems to maximise the possibility that patients 
stay in the programme, particularly younger and less 
educated individuals. Also, appropriate incentives should 
be put in place to keep programme staff fully engaged 
and avoid programme fatigue. Future studies should 
further identify causes of loss to follow-up and find effec-
tive ways to adapt programmes accordingly (eg, access to 
treatment within the community and targeted behaviour 
change messaging) to ensure that most of the patients 
recruited stay long-term in the programme. Future 
research may also want to focus on more difficult to reach 
patients who have lower levels of awareness and treatment 
on enrolment.
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